Casi Pharmaceuticals(OTC) CASIF

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focusing on developing and commercializing innovative therapies primarily in China and globally. Founded in 1991, CASI shifted its strategy to the Chinese market in 2012, building a strong infrastructure focused on hematology oncology and other unmet medical areas. The company operates mainly through its subsidiaries in China, utilizing a market-oriented approach to identify potential products with broad market acceptance.

Products and Services

EVOMELA (Melphalan for Injection): Used as a conditioning treatment for stem cell transplantation and for treating multiple myeloma in China.

CNCT19 (CD19 CAR-T): A potential treatment for hematological malignancies developed with Juventas Cell Therapy Ltd.

BI-1206: An antibody targeting FcRIIB to enhance immunotherapy efficacy for both hematological and solid cancers.

CB-5339: A novel inhibitor targeting protein homeostasis pathways for cancer treatment, licensed from Cleave Therapeutics, Inc.

CID-103: A monoclonal antibody for treating multiple myeloma, with global development rights.

What Makes CASI Pharmaceuticals, Inc. Special

CASI Pharmaceuticals stands out due to its strategic focus on the Chinese market, leveraging partnerships with global companies to expand its oncology portfolio. Its in-licensing approach strengthens its pipeline, and its experienced leadership expertly navigates regulatory landscapes to foster growth.

Five Things You Need to Know

CASI launched its first commercial product, EVOMELA, in China in August 2019.

The company has focused operations primarily in China, with key subsidiaries in Beijing and Wuxi.

CASI's pipeline includes multiple cancer therapies addressing significant unmet medical needs.

It uses strategic partnerships and in-licensing agreements to enhance its R&D capabilities.

The company aims to capitalize on China's growing demand for advanced healthcare solutions.